Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T2HN
|
|||
| Former ID |
DNC008979
|
|||
| Drug Name |
N-(Naphthalene-2-yl)ethyl-ETAV
|
|||
| Synonyms |
N-(Naphthalene-2-yl)ethyl-ETAV; CHEMBL493689
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H40N4O8
|
|||
| Canonical SMILES |
CC(C)C(C(=O)O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)O)NCCC1=CC2=CC=CC=C2C=C1
|
|||
| InChI |
1S/C29H40N4O8/c1-16(2)24(29(40)41)32-26(37)17(3)31-28(39)25(18(4)34)33-27(38)22(11-12-23(35)36)30-14-13-19-9-10-20-7-5-6-8-21(20)15-19/h5-10,15-18,22,24-25,30,34H,11-14H2,1-4H3,(H,31,39)(H,32,37)(H,33,38)(H,35,36)(H,40,41)/t17-,18?,22-,24-,25-/m0/s1
|
|||
| InChIKey |
BVNXVJDQOOZPCM-FZDDQCGTSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Presynaptic density protein 95 (DLG4) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Hippo signaling pathway | |||
| Glutamatergic synapse | ||||
| Huntington's disease | ||||
| Cocaine addiction | ||||
| Panther Pathway | Huntington disease | |||
| Pathway Interaction Database | ErbB4 signaling events | |||
| Reactome | Trafficking of AMPA receptors | |||
| Unblocking of NMDA receptor, glutamate binding and activation | ||||
| CREB phosphorylation through the activation of CaMKII | ||||
| Ras activation uopn Ca2+ infux through NMDA receptor | ||||
| RHO GTPases activate CIT | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| L1CAM interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.